S. 1097

119th Congress

Reported

Interagency Patent Coordination and Improvement Act of 2025

Sponsored byDemocrat:Sen. Durbin, Richard J. [D-IL]IL· Introduced 24 March 2025

4

Cosponsors

6

Actions

0

Amendments

0

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

10 April 2025·1 year ago

Summary

Introduced in Senate · Updated 17 June 2025

Interagency Patent Coordination and Improvement Act of 2025

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.

Timeline

6 actions

  1. Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

    10 April 2025 · Calendars

  2. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 April 2025 · Committee

  3. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 April 2025 · Committee

  4. Committee on the Judiciary. Ordered to be reported with amendments favorably.

    3 April 2025 · Committee

  5. Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)

    24 March 2025 · IntroReferral

  6. Introduced in Senate

    24 March 2025 · IntroReferral

Sponsorship

4 cosponsors

Cosponsors

  • Democrat250%
  • Republican250%

Classification

Policy area

Commerce

Legislative subjects

Drug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Intellectual propertyIntergovernmental relations
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.